Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
65
Years old
Gender
All
Therapeutic area :
Allergy
Disease :
Allergic rhinitis
Study medication :
L-mequitazine (Xyzall®)
Phase :
Phase II
Start Date :
10 May 2006
End date :
14 August 2006
Study ID :
V00114 CP 201
EudraCT/CTIS number :
2005-005975-13
Send by email